North West Coast
Strategic Clinical Networks

Chemotherapy protocol

Drug regimen
Concurrent Gemcitabine

Indication for use
Concurrent chemo/radiotherapy bladder

Regimen

Day	Drug	Route	Fluid	Time
1	Gemcitabine 100mg/m^2	IV	250ml 0.9% NaCl	2 – 4 hours pre XRT, 30 min infusion
8	Gemcitabine 100mg/m^2	IV	250ml 0.9% NaCl	2 – 4 hours pre XRT, 30 min infusion
15	Gemcitabine 100mg/m^2	IV	250ml 0.9% NaCl	2 – 4 hours pre XRT, 30 min infusion
22	Gemcitabine 100mg/m^2	IV	250ml 0.9% NaCl	2 – 4 hours pre XRT, 30 min infusion

Investigation prior to initiating treatment
FBC, U&Es, LFTs,

Investigations and consultations prior to each cycle
Day 1, Day 8, Day 15, Day 22 – FBC, U&Es, LFTs,

Acceptable levels for treatment to proceed
(if outside these levels, defer one week or contact consultant)

Day 1, Day 8, Day 15, Day 22: WCC >3.0, neutrophils >1.5, platelets >100

Side Effects
Nausea & vomiting, bone marrow suppression, neutropenia, thrombocytopenia, peripheral neuropathy, nephrotoxicity, audio-toxicity, pulmonary-toxicity (Pneumonitis) (altered LFT's from gemcitabine), flu-like symptoms, allergic rash

Dose Modification Criteria
None specific

Specific Information on Administration
Do not reduce rate of administration of gemcitabine.

THIS PROTOCOL HAS BEEN DIRECTED BY DR BIRTLE DESIGNATED LEAD CLINICIAN FOR UROLOGICAL CANCER
RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE

Date **June 2017**
Review **June 2019**
Version **3**